We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Report from the Advisory Council on the Misuse of Drugs (ACMD) on consumer cannabidiol (CBD) products.
1. Introduction 1.1. Consumer Cannabidiol (CBD) products (i.e. CBD…
Kit Malthouse MP Minister of State for Crime, Policing and Justice 2…
Kit Malthouse MP Minister of State for Crime Reduction and Policing 2…
Rt Hon Chris Philp MP Minister of State for Crime, Policing and Fire 2…
Letter from Kit Malthouse MP to Professor Owen Bowden-Jones, Chair of the Advisory Council on the Misuse of Drugs (ACMD).
Professor Owen Bowden-Jones Chair, Advisory Council on the Misuse of Drugs…
This factsheet outlines the domestic control measures that apply to cannabis, cannabidiol (CBD) and controlled cannabinoids.
This factsheet represents the Home Office’s view on the domestic control…
The Government Chemist team has published guidance on analytical limits for controlled cannabinoids in specified products containing cannabidiol (CBD)
FCDO travel advice for Armenia. Includes safety and security, insurance, entry requirements and legal differences.
FCDO travel advice for Hong Kong. Includes safety and security, insurance, entry requirements and legal differences.
Information about controlled drugs licences for companies that possess, manufacture, produce or supply controlled drugs in England, Wales or Scotland.
Atnahs Pharma UK Ltd has informed the MHRA that the batches of Clobazam Atnahs 5mg/5ml and 10mg/5ml Oral Suspension listed in this notification do not contain the most up to date safety information.
Letter to the Home Office regarding the appropriate Schedule for the cannabis-based product for medicinal use, Epidyolex, under the Misuse of Drugs Regulations 2001.
FCDO travel advice for Nepal. Includes safety and security, insurance, entry requirements and legal differences.
Latest FCDO travel advice for South Africa including on entry requirements, safety and security and local laws and customs
The VMD considers that veterinary products containing Cannabidiol are veterinary medicines.
This circular draws attention to the content of the Statutory Instrument (SI) 2020 No. 559 amending The Misuse of Drugs Regulations 2001.
Healthcare professionals should be vigilant for suspected adverse reactions and safety concerns associated with e-cigarettes and e-liquids, commonly known as vapes. Please report adverse reactions to the Yellow Card scheme a…
The Medicines and Healthcare products Regulatory Agency has issued an opinion on the regulatory status of products containing CBD
Advisory Council on the Misuse of Drugs (ACMD) call for evidence on cannabinoids in CBD products.
The government responds to the ACMD reports on cannabis-based products for medicinal use (CBPMs) in humans.
The Advisory Council on the Misuse of Drugs has now published its advice on consumer cannabidiol (CBD) to which the GC team has contributed with a series of activities
Advice for Retailers and Producers
Overview of the analysis of novel foods for the presence of cannabidiol
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).